Hepatitis C, insulin resistance, and steatosis

Current Hepatitis Reports

Volumn 6, Issue 4, 2007, Pages 129-137

  Torres, Dawn M ^b   Harrison, Stephen A ^a  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; ASCORBIC ACID; ATORVASTATIN; FATTY ACID; FATTY ACID SYNTHASE; GLUTATHIONE; GLYCYRRHIZIC ACID; INTERLEUKIN 6; METFORMIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PEGINTERFERON; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PIOGLITAZONE; RIBAVIRIN; SCHISANDRA CHINENSIS EXTRACT; SILYMARIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; THIOCTIC ACID; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID; VITAMIN B COMPLEX;

DISEASE ASSOCIATION; DRUG TOLERABILITY; FATTY LIVER; GENETIC PREDISPOSITION; GENOTYPE; GLUCOSE METABOLISM; HEPATITIS C; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID PEROXIDATION; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; PROTEIN EXPRESSION; RACE DIFFERENCE; RELAPSE; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION; WEIGHT REDUCTION;

EID: 37049023006     PISSN: 15403416     EISSN: 15410706     Source Type: Journal    
DOI: 10.1007/s11901-007-0015-6     Document Type: Review

References (71)

1. Armstrong GL, Wasley A, Simard EP, et al.: The prevalence of hepatitis C virus infection in the United States, 1992 through 2002. Ann Intern Med 2006, 144:705-714.
2. Bialek SR, Terrault NA: The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis 2006, 10:697-715.
3. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB: Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 2007, 14:107-115.
4. Browning JD, Szeczepaniack LS, Dobbins R, et al.: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
5. •• Leandro G, Mangia A, Hui J, et al.: Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: A meta-analysis of individual patient data. Gastroenterology 2006, 130:1636- 1642. This large meta-analysis of 3068 patients solidifies the link between steatosis and fibrosis in chronic hepatitis C.
6. Lonardo A, Adinolfi L, Loria P, et al.: Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004, 126:586-597.
7. Ong JP, Younossi ZM, Speer C, et al.: Chronic hepatitis C and superimposed non-alcoholic fatty liver disease. Liver 2001, 21:266-271.
8. Brunt EM, Ramrakhiani S, Cordes BG, et al.: Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol 2003, 16:49-56.
9. Conjeevaram HS, Kleiner DE, Everhart JE, et al.: Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007, 45:80-87.
10. Verma S, Bonacini M, Govindarajan S, et al.: More advanced hepatic fibrosis in Hispanics with chronic hepatitis C infection: role of patient demographics, hepatic necroinflammation, and steatosis. Am J Gastroenterol 2006, 101:1817-1823.
11. Hu KQ, Currie SL, Shen H, et al.: Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of US veterans. Dig Dis Sci 2007, 52:570-578.
12. Walsh MJ, Jonsson JR, Richardson MM, et al.: Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signaling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006, 55:529-535.
13. Tsochatzis E, Papatheodoridis GV, Archimandritis AJ: The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol 2006, 101:2629-2640.
14. Durante-Mangoni, Zampino R, Marrone A, et al.: Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumor necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther 2006, 24:1349-1357.
15. Jonsson JR, Moschen AR, Hickman IJ, et al.: Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol 2005, 43:929-936.
16. Widjaja A, Wedemeyer H, Tillman HL, et al.: Hepatitis C and the leptin system: bound leptin levels are elevated in patients with hepatitis C and decrease during antiviral therapy. Scand J Gastroenterol 2001, 36:426-431.
17. Romero-Gomez M, Castellano-Megias VM, Grande L, et al.: Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. Am J Gastroenterol 2003, 98:1135-1141.
18. Lecube A, Hernandez C, Genesca J, Simo R: Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients. Diabetes Care 2006, 29:1096-1101.
19. Metha SH, Brancati FL, Sulkowski MS, et al.: Prevalence of type 2 diabetes mellitus: what is the connection? Ann Intern Med 2000, 133:592-599.
20. Mehta SH, Brancati FL, Strathdee SA, et al.: Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003, 38:50-56.
21. • Shintani Y, Fujie H, Miyoshi H, et al.: Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004, 126:840-848. This study clearly demonstrates virally mediated development of insulin resistance.
22. Moriya K, Yotsuyanagi H, Shintani Y, et al.: Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997, 78:1527-1531.
23. Kawaguchi T, Ide T, Taniguchi E, et al.: Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007, 102:570-576.
24. Aytug S, Reich D, Sapiro LE, et al.: Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 2003, 38:1384-1392.
25. Miyamoto H, Moriishi K, Moriya K, et al.: Involvement of the PA28gamma-dependent pathway in insulin resistance induced by hepatitis C core protein. J Virol 2006, 81:1727-1735.
26. Moriishi K, Mochizuki, Moriya K et al.: Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and carcinogenesis. Proc Natl Acad Sci USA 2007, 104:1611-1666.
27. Castera L, Chouteau P, Hezode C, et al.: Hepatitis C virus-induced hepatocellular steatosis. Am J Gastroenterol 2005, 100:711-715.
28. Moriya K, Nakagawa K, Santa T, et al.: Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 2001, 61:4365-4370.
29. Okuda M, Li K, Beard MR, et al.: Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002, 122:366-375.
30. Cheng Y, Dharancy S, Malapel M, Desreumaux P: Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor alpha and carnitine palmitoyl acyl-CoA transferase IA. World J Gastroenterol 2005, 11:7591-7596.
31. Dharancy S, Malapel M, Perletmuter G, et al.: Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 2005, 128:334-342.
32. Lonardo A, Loria P, Adinolfi LE, et al.: Hepatitis C and steatosis: a reappraisal. J Viral Hepat 2006, 13:73-80.
33. Hourioux C, Patient R, Morin A, et al.: The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. Gut 2007, 56(9):1302-1308.
34. Jackel-Cram C, Babiuk L, Liu Q: Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype 1-b core. J Hepatol 2007, 46:999-1008.
35. Mirandola S, Realdon S, Iqbal J, et al.: Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 2006, 130:1661-1669.
36. Lok AS, Everhart JE, Chung RT, et al.: Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clinical Gastroenterol Hepatol 2007, 5:245-254.
37. Castera L, Hezode C, Roudot-Thoraval F, et al.: Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003, 52:288-292.
38. Westin J, Nordlinder H, Lagging M, et al.: Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002, 37:837-842.
39. Hui JM, Sud A, Farrell GC, et al.: Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003, 125:1695-1704.
40. Taura N, Ichikawa T, Hamasaki, et al.: Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. Am J Gastroenterol 2006, 101:2752-2759.
41. D'Souza R, Sabin CA, Foster GR: Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005, 100:1509-1515.
42. Piche T, Vandenbos F, Abakar-Mahamat A, et al.: The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J Viral Hepatol 2004, 11:91-96.
43. Poynard T, Ratziu V, McHutchinson J, et al.: Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003, 38:75-85.
44. Patton HM, Patel K, Behling C, et al.: The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004, 40:484-490.
45. Westin J, Lagging M, Dhillon AP, et al.: Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepatol 2007, 14:29-35.
46. Harrison SA, Brunt EM, Qazi RA, et al.: Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005, 3:604-609.
47. •• Romero-Gomez M, Del Mar Viloria M, Andrade R, et al.: Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005, 128:636-641. This prospective study showed insulin resistance, fibrosis, and genotype are independent predictors of the response to antiviral therapy in CHC patients treated with pegylated interferon and ribavirin.
48. Choi J, Ou JH: Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol 2006, 290:847-851.
49. DiBona D, Cippitelli M, Fionda C, et al.: Oxidative stress inhibits IFN-alpha-induced antiviral gene expression by blocking the JAK-STAT pathway. J Hepatol 2006, 45:271-279.
50. Zimmerer JM, Lesinski GB, Kondadasula SV, et al.: IFN-alpha-induced signal transduction, gene expression and antitumor activity. J Immunol 2007, 178:4832-4845.
51. Sanyal AJ, Chand N, Comar K, Mirshahi F: Hyperinsulinemia blocks the inhibition of hepatitis C virus replication by interferon: the potential mechanism for failure of interferon therapy in subjects with HCV and nonalcoholic fatty liver disease. Hepatology 2004, 40:39A.
52. Harrison SA: Correlation between insulin resistance and hepatitis C viral load. Hepatology 2005, 42:987-1000.
53. Charlton MR, Pockros PJ, Harrison SA: Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006, 43:1177-1186.
54. Bressler B, Wang K, Gries JM, et al.: Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN Alpha2A(40KD). Hepatology 2005, 42:661A.
55. Fried M, Jensen D, Rodriguez-Torres M, et al.: Improved sustained virological response (SVR) rates with higher, fixed doses of peginterferon Alfa-2A (40KD) plus ribavirin in patients with difficult to cure characteristics. Hepatology 2006, 44:314A.
56. McHutchison JG, Poynard T, Pianko S, et al.: The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology 2000, 199:1317-1323.
57. Melhem A, Stern M, Shibolet O, et al.: Treatment of chronic hepatitis C virus infection via antioxidants. J Clin Gastroenterol 2005, 39:737-742.
58. Tanaka K, Kondo M, Sakaguchi T, et al.: Efficacy of ursodeoxycholic acid in combination with interferon-alpha in treating chronic hepatitis C: results of long-term follow-up trial. J Gastroenterol Hepatol 1996, 11:1155-1160.
59. Houglum K, Venkataramani A, Lyche K, et al.: A pilot study of the effects of D-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997, 113:1069-1073.
60. Look MP, Gerard A, Rao GS, et al.: Interferon/antioxidant combination therapy for chronic hepatitis C-a controlled pilot trial. Antiviral Res 1999, 43:113-122.
61. Puri P, Sanyal A: Role of obesity, insulin resistance, and steatosis in hepatitis C virus infection. Clin Liver Dis 2006, 10:793-819.
62. Monazahian M, Bohme I, Bonk S, et al.: Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 1999, 57:223-229.
63. Kim SS, Peng LF, Lin W, et al.: A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication. Gastroenterology 2007, 132:311-320.
64. O'Leary JG, Chan JL, McMahon CM, Chung RT: Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology 2007, 45:895-898.
65. Hickman IJ, Clouston AD, Macdonald GA, et al.: Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002, 51:89-94.
66. Harrison SA: Liver disease in patients with diabetes mellitus. J Clin Gastroenterol 2006, 40:68-76.
67. Belfort R, Harrison SA, Brown K, et al.: A placebo controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Eng J Med 2006, 355:2297-2307.
68. Kanatani Y, Usui I, Ishizuka K, et al.: Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression. Diabetes 2007, 56:796-803.
69. Yaginuma R, Ikejima K, Okumura K, et al.: Hepatic steatosis is a predictor of poor response to interferon alpha-2b and ribavirin combination therapy in Japanese patients with chronic hepatitis C. Hepatol Res 2006, 35:19-25.
70. Tarantino G, Conca P, Sorrentino P, et al.: Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. J Gastroenterol Hepatol 2006, 21:1266-1288.
71. Guidi M, Muratori P, Granito A, et al.: Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin. Aliment Pharmacol Ther 2005, 22:943-949.